The FLT3 internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112
- PMID: 16103085
- DOI: 10.1158/0008-5472.CAN-04-2263
The FLT3 internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112
Abstract
Internal tandem duplication (ITD) mutations in the FLT3 tyrosine kinase have been detected in approximately 20% of acute myeloid leukemia (AML) patients. Patients harboring FLT3/ITD mutations have a relatively poor prognosis. FLT3/ITD results in constitutive autophosphorylation of the receptor and factor-independent survival. Previous studies have shown that FLT3/ITD activates the signal transducers and activators of transcription 5 (STAT5), p42/p44 mitogen-activated protein kinase [MAPK; extracellular signal-regulated kinase (ERK) 1/2], and phosphatidylinositol 3-kinase/Akt pathways. We herein provide biochemical and biological evidence that ribosomal S6 kinase 1 (RSK1) and protein kinase A (PKA) are the two principal kinases that mediate the antiapoptotic function of FLT3/ITD via phosphorylation of BAD at Ser112. Inhibiting both MAPK kinase (MEK)/ERK and PKA pathways by a combination of U0126 (10 micromol/L) and H-89 (5 micromol/L) reduced most of BAD phosphorylation at Ser112 and induced apoptosis to a level comparable with that induced by FLT3 inhibitor AG1296 (5 micromol/L) in BaF3/FLT3/ITD cells. RNA interference of RSK1 or PKA catalytic subunit reduced BAD phosphorylation and induced apoptosis. The MEK inhibitor U0126 and/or the PKA inhibitor H-89 greatly enhanced the efficacy of the FLT3 inhibitor AG1296, suggesting that combining FLT3/ITD downstream pathway inhibition with FLT3 inhibitors may be a viable therapeutic strategy for AML caused by a FLT3/ITD mutation.
Similar articles
-
Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.Leukemia. 2002 Oct;16(10):2027-36. doi: 10.1038/sj.leu.2402674. Leukemia. 2002. PMID: 12357354
-
Constitutively activated FLT3 phosphorylates BAD partially through pim-1.Br J Haematol. 2006 Sep;134(5):500-9. doi: 10.1111/j.1365-2141.2006.06225.x. Br J Haematol. 2006. PMID: 16869825
-
FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins.Oncogene. 2004 Apr 22;23(19):3338-49. doi: 10.1038/sj.onc.1207456. Oncogene. 2004. PMID: 14981546
-
Flt3 receptor tyrosine kinase as a drug _target in leukemia.Curr Pharm Des. 2004;10(16):1867-83. doi: 10.2174/1381612043384394. Curr Pharm Des. 2004. PMID: 15180525 Review.
-
FLT3 in human hematologic malignancies.Leuk Lymphoma. 2002 Aug;43(8):1541-7. doi: 10.1080/1042819021000002866. Leuk Lymphoma. 2002. PMID: 12400596 Review.
Cited by
-
Zinc and the ERK kinases in the developing brain.Neurotox Res. 2012 Jan;21(1):128-41. doi: 10.1007/s12640-011-9291-6. Epub 2011 Nov 18. Neurotox Res. 2012. PMID: 22095091 Free PMC article. Review.
-
Zinc deficiency and neurodevelopment: the case of neurons.Biofactors. 2010 Mar-Apr;36(2):117-24. doi: 10.1002/biof.91. Biofactors. 2010. PMID: 20333753 Free PMC article. Review.
-
FLT3-ITD Activates RSK1 to Enhance Proliferation and Survival of AML Cells by Activating mTORC1 and eIF4B Cooperatively with PIM or PI3K and by Inhibiting Bad and BIM.Cancers (Basel). 2019 Nov 20;11(12):1827. doi: 10.3390/cancers11121827. Cancers (Basel). 2019. PMID: 31756944 Free PMC article.
-
{beta}-Arrestin-2 Mediates Anti-apoptotic Signaling through Regulation of BAD Phosphorylation.J Biol Chem. 2009 Mar 27;284(13):8855-65. doi: 10.1074/jbc.M808463200. Epub 2009 Jan 26. J Biol Chem. 2009. PMID: 19171933 Free PMC article.
-
_targeting FLT3-ITD signaling mediates ceramide-dependent mitophagy and attenuates drug resistance in AML.Blood. 2016 Oct 13;128(15):1944-1958. doi: 10.1182/blood-2016-04-708750. Epub 2016 Aug 18. Blood. 2016. PMID: 27540013 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials
Miscellaneous